Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Another JDRF Partner Moves Research Forward With Collaboration Agreement For Diabetes Treatment
The Juvenile Diabetes Research Foundation said recently that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials.
generic viagra online
Insight Into How Brain Stem Cells Develop Into Cells Which Repair Damaged Tissue
The joint research, funded by the National Multiple Sclerosis Society and the UK MS Society as well as the National Institutes of Health and Howard Hughes Medical Institute, was conducted by scientists at the University of California San Francisco (UCSF) and University of Cambridge and was published in the journal Genes and Development.
News of the day
GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results At Endocrine Society Annual Meeting
GTx, Inc. (Nasdaq: GTXI) announced results of a Phase II clinical trial evaluating Ostarine™ (MK-2866), an investigational selective androgen receptor modulator (SARM), in patients with cancer induced muscle loss, also known as cancer cachexia. In the study, Ostarine treatment led to statistically significant increase in lean body mass (LBM) and improvement in muscle performance measured by stair climb in patients with cancer cachexia compared to baseline in both the Ostarine 1 mg and 3 mg treatment cohorts. These study results were the subject today of an oral podium presentation at the 2009 Annual Meeting of the Endocrine Society in Washington.
Health Insurance

Hepatitis B Virus Mutations May Predict Risk Of Liver Cancer

Certain mutations in the DNA of the hepatitis B virus (HBV) are associated with the development of liver cancer and may help predict which patients with HBV infections are at increased risk of the disease, according to a large meta-analysis in the Journal of the National Cancer Institute, published online July 2. HBV infection is a known cause of hepatocellular carcinoma (HCC), the most common form of liver cancer. Previous studies have looked at whether patients with specific mutations in the viral DNA may be at increased risk of developing the cancer, but most of the studies were small and they produced conflicting results. This meta-analysis, conducted by Guangwen Cao, M.D., Ph.D., of the Second Military Medical University in Shanghai and colleagues, included 43 studies with a total of 11,582 HBV-infected participants, of whom 2,801 had HCC. The researchers found that certain mutations were associated with development of HCC and more prevalent as chronic HBV infection progressed from the asymptomatic state to liver cirrhosis or HCC. "Frequent examination of patients with chronic HBV infections for the presence of these mutations may be useful for identifying which patients require preventive antiviral treatment and for the prediction of HCC," the authors write. Steve Graff Journal of the National Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009